Our study demonstrated that among selected patients with advanced, previously treated cancer, PD-1/PD-L1 inhibitors, compared with conventional treatments (chemotherapy or targeted therapy), were associated with improvement in OS but not PFS. The gene discussed is PDCD1; the disease is cancer.